RxDoctor Payments Data

Bryan Vo, MD

Family Medicine · Alpharetta, GANPI 1477903961

Payments from drug & device makers

$5,570in general payments, 2019–2025

Across 253 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$651
  • Lilly USA, LLC$613
  • Novo Nordisk$528
  • AstraZeneca$450
  • AbbVie$289
  • Pfizer$263
  • plus $3K from 43 others

What the payments were for

  • Speaking & faculty fees$2504%
  • Travel & lodging$10%
  • Food & beverage$5,31895%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,570 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$48,017
Medicare patients
97
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$27,680
JardianceEmpagliflozin24$19,227
MounjaroTirzepatide11$16,798
Bupropion XlBupropion Hcl16$1,033
Atorvastatin Calcium107$752
Ezetimibe26$702
Albuterol Sulfate HfaAlbuterol Sulfate23$544
Valsartan16$468
Rosuvastatin Calcium86$446
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine16$419
Metformin Hcl30$403
Losartan Potassium61$396
Olmesartan Medoxomil23$385
Fluticasone Propionate21$374
Duloxetine Hcl17$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$528$27,68028 claims
Boehringer IngelheimJardiance$115$19,22724 claims
Lilly USA, LLCMounjaro$613$16,79811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →